Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months

Arcus Biosciences reports 26.7-month median survival and 59% response rate in Phase 2 cancer study with domvanalimab ...
Healio

FDA approves Qivigy for adults with primary humoral immunodeficiency

The FDA has approved Kedrion Biopharma’s Qivigy, a 10% IV immunoglobulin therapy, for treating adults who have primary ...

Shattuck Labs, Inc. (STTK) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 Transcript

Shattuck Labs, Inc. ( NASDAQ: STTK) The United European Gastroenterology (UEG) Congress UEG Week 2025 October 8, 2025 10:00 AM EDT ...
Scientific Research Publishing

Case Report: Splenic Rupture Post-Caesarean Section ()

Splenic Rupture Post-Caesarean Section. Open Journal of Nursing, 15, 848-862. doi: 10.4236/ojn.2025.1510061 . The spleen is a ...

BioVie Inc. (BIVI) Discusses Latest Clinical Advancements, Investment Potential, And Upcoming Data Readouts Transcript

Discover BioVie's latest clinical advancements in Parkinson's, long COVID, and ascites. Learn about investment potential and upcoming data readouts.
Becker's Hospital Review

75% time savings, 4x capacity increases: How infusion teams are transforming intake workflows with AI

I speak with infusion leaders every day—from major health systems to independent infusion practices—and the same challenge comes up time and again: ...

Experts warn the IV hydration craze may be putting you at risk

IV hydration spas are popping up across the United States, offering pricey vitamin infusions that promise energy, detox or ...

Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 ...